Skip to main content
Premium Trial:

Request an Annual Quote

Circulogene Theranostics Partners With UAB to Research Liquid Biopsy Effectiveness

NEW YORK (GenomeWeb) – Alabama-based molecular diagnostics company Circulogene Theranostics announced today that it has signed a research agreement with the University of Alabama Birmingham (UAB) Comprehensive Cancer Center to investigate the efficacy of liquid biopsy for tumor detection and monitoring.

The company will conduct a clinical trial with the cancer center to compare how effective liquid biopsies are compared to traditional tissue biopsies, including Circulogene's own liquid biopsy technology. The firm has developed circulating cell-free DNA liquid biopsy products for personalized testing of 10 tumor types, including breast, lung, and colon cancer.

"We're eager to work with such a highly respected group of researchers who recognize the unique ability of our proprietary enrichment technique to provide maximal DNA data output with minimal input," said Circulogene CEO Mike Mullen in a statement. "We look forward to aligning with the world-renowned UAB cancer center to further evaluate the effectiveness of our droplet-volumes-of-blood technology."